Reviewing the Potential of Psychedelics for the Treatment of PTSD
Open accessThe DOI matches its Crossref record; 168 of the 168 references it cites were found in a registry or an index.
Abstract
There are few medications with demonstrated efficacy for the treatment of posttraumatic stress disorder (PTSD). Treatment guidelines have unequivocally designated psychotherapy as a first line treatment for PTSD. Yet, even after psychotherapy, PTSD often remains a chronic illness, with high rates of psychiatric and medical comorbidity. Meanwhile, the search for and development of drugs with new mechanisms of action has stalled. Therefore, there is an urgent need to explore not just novel compounds but novel approaches for the treatment of PTSD. A promising new approach involves the use of psychedelic drugs. Within the past few years, 2 psychedelics have received breakthrough designations for psychiatric indications from the US Food and Drug Administration, and several psychedelics are currently being investigated for the treatment of PTSD. This review discusses 4 types of compounds: 3,4-methylenedioxymethamphetamine, ketamine, classical psychedelics (e.g., psilocybin and lysergic acid diethylamide), and cannabinoids. We describe the therapeutic rationale, the setting in which they are being administered, and their current state of evidence in the treatment of PTSD. Each compound provides unique qualities for the treatment of PTSD, from their use to rapidly target symptoms to their use as adjuncts to facilitate psychotherapeutic treatments. Several questions are formulated that outline an agenda for future research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies have also pointed out a potential of use of MDMA assisted psychotherapy as a minimal risk therapeutic method that works by reducing fear response to traumatic memories, while enhancing introspection and increasing interpersonal trust, which improves the patient-therapist relationship and so, the effectiveness of the therapy (Krediet et al., 2020).”
From Virtual reality and psychedelics for the treatment of psychiatric disease: A systematic literature review (2020) · doi:10.36131/cnfioritieditore20200606 · cites this paper as Krediet et al., 2020
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“To our knowledge, MDMA treatment efficacy is so far mainly assessed in PTSD patients, indicating moderate to large effects (Krediet et al., 2020;Bahji et al., 2020).”
From Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review (2022) · cites this paper as Krediet et al., 2020
The cited source says what the claim attributes to it.
In the citing paper
“Ketamine has also been studied because of the rapid antidepressant properties that it exhibits (Krediet et al., 2020).”
From Virtual reality and psychedelics for the treatment of psychiatric disease: A systematic literature review (2020) · doi:10.36131/cnfioritieditore20200606 · cites this paper as Krediet et al., 2020
The cited source says what the claim attributes to it.
In the citing paper
“Ketamine has also been considered for the treatment of PTSD, although information on this matter is still lacking (Krediet et al., 2020; Reiff et al., 2020).”
From Virtual reality and psychedelics for the treatment of psychiatric disease: A systematic literature review (2020) · doi:10.36131/cnfioritieditore20200606 · cites this paper as Krediet et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Mithoefer, M. C., Feduccia, A. A., Jerome, L., Mithoefer, A., Wagner, M., Walsh, Z., Hamilton, S., Yazar-Klosinski, B., Emerson, A., & Doblin, R. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05249-5 · Cited by 359 · cited 3×
“Integrated within a psychotherapeutic treatment, 2 to 3 sessions with MDMA have shown the ability to induce significant and sustained reductions in PTSD symptoms (Mithoefer et al., 2019).”
BackgroundMethodRetractedAntidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., Keurentjes, J. C., Lang, S., Misso, K., Ryder, S., et al. (2015) · JAMA · doi:10.1001/jama.2015.6358 · Cited by 2,169 · cited 1×
“pain relief, multiple sclerosis and epilepsy) have been growing again (Whiting et al., 2015; Haney and Hill, 2018).”
BackgroundSynaptic plasticity and depression: new insights from stress and rapid-acting antidepressants
Duman, R. S., Aghajanian, G. K., Sanacora, G., & Krystal, J. H. (2016) · Nature Medicine · doi:10.1038/nm.4050 · Cited by 1,750
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540 · cited 2×
“Psilocybin has been studied for the treatment of depression (Carhart-Harris et al., 2016, 2017), tobacco and alcohol addiction (Johnson et al., 2014, 2017; Bogenschutz et al., 2015, 2018), obsessive-compulsive disorder (Moreno et al., 2006), and depression and anxiety in patients with…”
BackgroundNichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
Research works printed but not linked: 5
- Gasser P (1996) Die psycholytische Psychotherapie in der Schweiz von 1988–1993. Schweiz Arch Neurol Psychiatr 147: 59– 65
- Grof S (1980) LSD psychotherapy. Pomona, CA: Hunter House.
- Ossebaard H, Maalsté N (1999) The bastiaans method of drug-assisted psychotherapy. In: MAPS Bulletin 9: 3– 9.
- Passie T (1997) Psycholytic and psychedelic therapy research 1931–1995: a complete international bibliography. Hannover, Germany: Laurentius Publ.
- Passie T (2012) Healing with entactogens: therapist and patient perspectives on MDMA-assisted group psychotherapy. Santa Cruz, CA: Multidisciplinary Association for Psychedelic Studies (MAPS).
Cited by
De Gregorio, D., Aguilar-Valles, A., Preller, K. H., Heifets, B. D., Hibicke, M., Mitchell, J., & Gobbi, G. (2021) · The Journal of Neuroscience · doi:10.1523/jneurosci.1659-20.2020 · Cited by 259
The Therapeutic Potential of Psilocybin
Lowe, H., Toyang, N., Steele, B., Valentine, H., Grant, J., Ali, A., Ngwa, W., & Gordon, L. (2021) · Molecules · doi:10.3390/molecules26102948 · Cited by 242
Breeksema, J. J., Niemeijer, A. R., Krediet, E., Vermetten, E., & Schoevers, R. A. (2020) · CNS Drugs · doi:10.1007/s40263-020-00748-y · Cited by 224
Self-citationTreatment of Posttraumatic Stress Disorder: A State-of-the-art Review
Burback, L., Brémault-Phillips, S., Nijdam, M. J., McFarlane, A., & Vermetten, E. (2024) · Current Neuropharmacology · doi:10.2174/1570159x21666230428091433 · Cited by 208
Self-citationSchimmers, N., Breeksema, J. J., Smith-Apeldoorn, S. Y., Veraart, J., van den Brink, W., & Schoevers, R. A. (2022) · Psychopharmacology · doi:10.1007/s00213-021-06027-y · Cited by 162
Self-citationPsychedelic therapy for depressive symptoms: A systematic review and meta-analysis
Ko, K., Kopra, E. I., Cleare, A. J., & Rucker, J. J. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.09.168 · Cited by 150
Psychedelics and health behaviour change
Teixeira, P. J., Johnson, M. W., Timmermann, C., Watts, R., Erritzoe, D., Douglass, H., Kettner, H., & Carhart-Harris, R. L. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211008554 · Cited by 87
Psilocybin facilitates fear extinction in mice by promoting hippocampal neuroplasticity
Du, Y., Li, Y., Zhao, X., Yao, Y., Wang, B., Zhang, L., & Wang, G. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002647 · Cited by 94
Kozłowska, U., Nichols, C. D., Wiatr, K., & Figiel, M. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15509 · Cited by 89
Psilocybin and MDMA for the treatment of trauma-related psychopathology
Bird, C. I. V., Modlin, N. L., & Rucker, J. J. H. (2021) · International Review of Psychiatry · doi:10.1080/09540261.2021.1919062 · Cited by 80
The Psychedelic Future of Post-Traumatic Stress Disorder Treatment
Zaretsky, T. G., Jagodnik, K. M., Barsic, R., Antonio, J. H., Bonanno, P. A., MacLeod, C., Pierce, C., Carney, H., Morrison, M. T., Saylor, C. F., et al. (2024) · Current Neuropharmacology · doi:10.2174/1570159x22666231027111147 · Cited by 104
The Need for Psychedelic-Assisted Therapy in the Black Community and the Burdens of Its Provision
Smith, D. T., Faber, S. C., Buchanan, N. T., Foster, D., & Green, L. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.774736 · Cited by 81
Psychedelic therapy's transdiagnostic effects: A research domain criteria (RDoC) perspective
Kelly, J. R., Gillan, C. M., Prenderville, J., Kelly, C., Harkin, A., Clarke, G., & O'Keane, V. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.800072 · Cited by 69
“Memory reconsolidation dysregulation is a cardinal clinical feature of PTSD andmemories can be strengthened or weakened according to new experiences.”
BackgroundInfluentialKetamine and its metabolites: Potential as novel treatments for depression
Zhang, K., Yao, Y., & Hashimoto, K. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109305 · Cited by 72
Gandy, S., Forstmann, M., Carhart-Harris, R. L., Timmermann, C., Luke, D., & Watts, R. (2020) · Health Psychology Open · doi:10.1177/2055102920978123 · Cited by 63
Wang, J., Gao, F., Cui, S., Yang, S., Gao, F., Wang, X., & Zhu, G. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106079 · Cited by 63
Shahar, O., Botvinnik, A., Esh-Zuntz, N., Brownstien, M., Wolf, R., Lotan, A., Wolf, G., Lerer, B., & Lifschytz, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214148 · Cited by 65
Singewald, N., Sartori, S. B., Reif, A., & Holmes, A. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109418 · Cited by 67
Kopra, E. I., Ferris, J., WINSTOCK, A. R., Kuypers, K. P. C., Young, A. H., & Rucker, J. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231158245 · Cited by 68
Varker, T., Watson, L., Gibson, K., Forbes, D., & O'Donnell, M. L. (2020) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2020.1817639 · Cited by 74
Psilocybin for Trauma-Related Disorders
Khan, A. J., Bradley, E., O’Donovan, A., & Woolley, J. (2022) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2022_366 · Cited by 67
LSD use in the United States: Trends, correlates, and a typology of us
Killion, B., Hai, A. H., Alsolami, A., Vaughn, M. G., Oh, P. S., & Salas‐Wright, C. P. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108715 · Cited by 58
Involvement of the brain–heart axis in the link between PTSD and cardiovascular disease
Seligowski, A. V., Webber, T. K., Marvar, P. J., Ressler, K. J., & Philip, N. S. (2022) · Depression and Anxiety · doi:10.1002/da.23271 · Cited by 59
Hinojosa, C. A., George, G. C., & Ben‐Zion, Z. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02558-w · Cited by 85
Review of otential sychedelic reatments for PTSD
Henner, R. L., Keshavan, M. S., & Hill, K. P. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120302 · Cited by 67
Argyri, E. K., Evans, J., Luke, D. P., Michael, P., Michelle, K., Rohani-Shukla, C., Suseelan, S., Prideaux, E., McAlpine, R. G., Murphy-Beiner, A., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0322501 · Cited by 59
Psychedelics in the treatment of eating disorders: Rationale and potential mechanisms
Calder, A. E., Mock, S., Friedli, N., Pasi, P., & Hasler, G. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2023.05.008 · Cited by 55
Pędzich, B. D., Rubens, S., Sekssaoui, M., Pierre, A., Schuerbeek, A. V., Marin, P., Bockaert, J., Valjent, E., Bécamel, C., & Bundel, D. D. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01324-2 · Cited by 56
Wießner, I., Olivieri, R., Falchi-Carvalho, M., Palhano-Fontes, F., Maia, L. O., Feilding, A., de Araújo, D. B., Ribeiro, S. T. G., & Tófoli, L. F. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.01.114 · Cited by 46
Kelley, D. P., Venable, K., Destouni, A., Billac, G., Ebenezer, P., Stadler, K., Nichols, C., Barker, S., & Francis, J. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00660 · Cited by 42
Psychotherapy with Psilocybin for Depression: Systematic Review
Dawood-Hristova, J. J., & Pérez‐Jover, V. (2023) · Behavioral Sciences · doi:10.3390/bs13040297 · Cited by 56
Relational Processes in Ayahuasca Groups of Palestinians and Israelis
Roseman, L., Ron, Y., Saca, A., Ginsberg, N., Luan, L., Karkabi, N., Doblin, R., & Carhart-Harris, R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.607529 · Cited by 40
Healy, C. J., Lee, K. A., & D'Andrea, W. M. (2021) · Chronic Stress · doi:10.1177/24705470211029881 · Cited by 48
Knowledge, Perceptions, and Use of Psychedelics among Individuals with Fibromyalgia
Glynos, N. G., Pierce, J. M., Davis, A. K., McAfee, J., & Boehnke, K. F. (2022) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2021.2022817 · Cited by 46
Psychedelics for acquired brain injury: a review of molecular mechanisms and therapeutic potential
Allen, J., Dames, S., Foldi, C. J., & Shultz, S. R. (2024) · Molecular Psychiatry · doi:10.1038/s41380-023-02360-0 · Cited by 47
Sottile, R., & Vida, T. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.991753 · Cited by 48
Davis, A. K., Xin, Y., Sepeda, N. D., & Averill, L. A. (2023) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2023.2220874 · Cited by 43
Veraart, J. K. E., van Westenbrugge, M., Palthe, J. E. V. W., van der Meij, A., Schoevers, R. A., & de Jong, J. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e15883 · Cited by 34
Serotonergic Psychedelics in Neural Plasticity
Lukasiewicz, K., Baker, J. J., Zuo, Y., & Lu, J. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.748359 · Cited by 31
Psychedelic Cognition—The Unreached Frontier of Psychedelic Science
Bălăeţ, M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.832375 · Cited by 39
Tiwari, P., Davoudian, P. A., Kapri, D., Vuruputuri, R. M., Karaba, L. A., Sharma, M., Zanni, G., Balakrishnan, A., Chaudhari, P. R., Pradhan, A., et al. (2024) · Neuron · doi:10.1016/j.neuron.2024.08.016 · Cited by 35
Psychedelic experiences and long-term spiritual growth: a systematic review
Schutt, W. A., Exline, J. J., Pait, K. C., & Wilt, J. A. (2024) · Current Psychology · doi:10.1007/s12144-024-06272-2 · Cited by 32
Exploring the regulatory framework of psychedelics in the US & Europe
Behera, H. K., Joga, R., Yerram, S., Karnati, P., Mergu, T., Gandhi, K., Sowndharya, M., Nathiya, D., Singh, R. P., Srivastava, S., et al. (2024) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2024.104242 · Cited by 28
Bharati, R., Kovach, K. A., Bonnet, J. P., Sayess, P., Polk, E., Harvey, K., & Vorbeck, L. (2022) · American Journal of Lifestyle Medicine · doi:10.1177/15598276211072506 · Cited by 31
Averill, L. A., & Abdallah, C. G. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2035358 · Cited by 23
Psychedelic Psychotherapy: Building Wholeness Through Connection
Vaid, G., & Walker, B. (2022) · Global Advances in Health and Medicine · doi:10.1177/2164957x221081113 · Cited by 26
Cao-Lei, L., Saumier, D., Fortin, J., & Brunet, A. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.857087 · Cited by 32
Shafiee, A., Bahri, R. A., Rafiei, M. A., Abianeh, F. E., Razmara, P., Jafarabady, K., & Amini, M. J. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241234247 · Cited by 24
RetractedBao, S., Jiang, H., Zhu, L., Yao, G., Han, P., Wan, X., Wang, K., Song, T., Liu, C., Wang, S., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109413 · Cited by 21
Brown, J. C., Kweon, J., Sharma, P., Siddiqi, S., Isserles, M., & Ressler, K. J. (2024) · Biological Psychiatry · doi:10.1016/j.biopsych.2024.06.010 · Cited by 25
Demin, K. A., Kupriyanova, O. V., Shevyrin, V. A., Derzhavina, K. A., Krotova, N. A., Ilyin, N. P., Kolesnikova, T. O., Galstyan, D. S., Kositsyn, Y. M., Khaybaev, A.-A. S., et al. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00123 · Cited by 23
Laabi, S., LeMmon, C., Vogel, C., Chacon, M., & Jimenez, V. M. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114940 · Cited by 23
Molecular and Medical Aspects of Psychedelics
Wojtas, A., & Gołembiowska, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010241 · Cited by 27
Modlin, N. L., Creed, M., Sarang, M., Maggio, C., Rucker, J., & Williamson, V. (2024) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s432537 · Cited by 24
Deciphering psilocybin: Cytotoxicity, anti-inflammatory effects, and mechanistic insights
Laabi, S., LeMmon, C., Vogel, C., Chacon, M., & Jimenez, V. M. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111753 · Cited by 20
Why Psychotropic Drugs Don't Cure Mental Illness—But Should They?
Ivanov, I., & Schwartz, J. M. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.579566 · Cited by 23
Tombari, R. J., Mundy, P. C., Morales, K. M., Dunlap, L. E., Olson, D. E., & Lein, P. J. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00642 · Cited by 20
Robison, R. J., Brendle, M., Moore, C., Cross, H., Helm, L., Darling, S., Thayer, S., Thielking, P. D., & Shannon, S. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2186285 · Cited by 25
Maples‐Keller, J. L., Watkins, L. E., Hellman, N. M., Phillips, N. L., & ROTHBAUM, B. O. (2024) · Biological Psychiatry · doi:10.1016/j.biopsych.2024.07.010 · Cited by 20
Pouyan, N., Khankahdani, Z. H., Sisi, F. Y., Lee, Y. L., Rosenblat, J. D., Teopiz, K. M., Lui, L. M. W., Subramaniapillai, M., Lin, K., Nasri, F., et al. (2022) · CNS Drugs · doi:10.1007/s40263-022-00944-y · Cited by 18
Sippel, L. M., Hamblen, J. L., Kelmendi, B., Alpert, J. E., Carpenter, L. L., Grzenda, A. L., Kraguljac, N. V., McDonald, W. M., Rodríguez, C. I., Widge, A. S., et al. (2024) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230950 · Cited by 18
Prajapati, S. K., Majumdar, S., Murari, S., MachhindraVadak, K., & Krishnamurthy, S. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00335 · Cited by 18
Kinderlehrer, D. A. (2025) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s500337 · Cited by 18
Trauma under psychedelics: how psychoactive substances impact trauma processing
Netzer, O., Magal, N., Stern, Y., Polinsky, T., Gross, R., Admon, R., & Salomon, R. (2025) · World Psychiatry · doi:10.1002/wps.21363 · Cited by 20
Posttraumatic Stress Disorder After a Psychedelic Experience, a Case Report
Rubin-Kahana, D. S., Hassan, A. N., & Foll, B. L. (2020) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000734 · Cited by 14
Psychoactive Drugs in the Management of Post Traumatic Stress Disorder: A Promising New Horizon
Elsouri, K. N., Kalhori, S., Colunge, D., Grabarczyk, G., Hanna, G., Carrasco, C., Espino, A. A., Francisco, A., Borosky, B., Bekheit, B., et al. (2022) · Cureus · doi:10.7759/cureus.25235 · Cited by 21
Somohano, V. C., & Bowen, S. W. (2022) · Journal of Integrative and Complementary Medicine · doi:10.1089/jicm.2021.0306 · Cited by 16
Gonda, X., Döme, P., Erdelyi-Hamza, B., Krause, S., Elek, L. P., Sharma, S., & Tarazi, F. I. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.05.010 · Cited by 15
The effect of low-dose psilocybin on brain neurotransmission and rat behavior
Bysiek, A., Wojtas, A., Szpręgiel, I., Wawrzczak‐Bargieła, A., Maćkowiak, M., & Gołembiowska, K. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111347 · Cited by 15
Nicholas, C. R. N., Banks, M. I., Lennertz, R. C., Wenthur, C. J., Krause, B. M., Riedner, B. A., Smith, R., Hutson, P. R., Sauder, C. J., Dunne, J. D., et al. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03059-8 · Cited by 19
Mohamed, A., Touheed, S., Ahmed, M., Hor, M., & Fatima, S. (2022) · Cureus · doi:10.7759/cureus.30919 · Cited by 20
Gómez-Busto, F. J., & Ortiz, M. I. (2020) · PubMed Central · doi:10.36131/cnfioritieditore20200606 · Cited by 12
“…psychotherapy as a minimal risk therapeutic method that works by reducing fear response to traumatic memories, while enhancing introspection and increasing interpersonal trust, which improves the patient-therapist relationship and so, the effectiveness of the therapy (Krediet et al., 2020).”
BackgroundInfluentialSchedule 1 barriers to research in the UK: An in-depth qualitative analysis
Howard, A., Neill, J. C., Schlag, A. K., & Lennox, C. (2021) · Drug Science Policy and Law · doi:10.1177/20503245211049313 · Cited by 15
A Review of MDMA-Assisted Therapy for Posttraumatic Stress Disorder
Lewis, B. R., & Byrne, K. (2023) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20220088 · Cited by 17
Mechanisms of psilocybin on the treatment of posttraumatic stress disorder
Choi, C. Q., Johnson, D. E., Chen-Li, D. C. J., & Rosenblat, J. D. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241286771 · Cited by 16
Zur Komorbidität von Posttraumatischer Belastungsstörung und Sucht in biopsychosozialer Perspektive
Kapfhammer, H. (2021) · Neuropsychiatrie · doi:10.1007/s40211-020-00384-4 · Cited by 12
Latimer, D. R., Stocker, M. D., Sayers, K., Green, J., Kaye, A. M., Abd-Elsayed, A. A., Cornett, E. M., Kaye, A. D., Varrassi, G., Viswanath, O., et al. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4414 · Cited by 28
Social Psychopharmacology: Novel Approaches to Treat Deficits in Social Motivation in Schizophrenia
Bershad, A. K., & de Wit, H. (2023) · Schizophrenia Bulletin · doi:10.1093/schbul/sbad094 · Cited by 12
Thaoboonruang, N., Lohitnavy, M., & Lohitnavy, O. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2399128 · Cited by 12
Evaluating the potential for psilocybin as a treatment for post-traumatic stress disorder
Miller, C., & Zoladz, P. R. (2024) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.124.002237 · Cited by 13
van der Gronde, T., Los, L., Herremans, A. H. J., Oosting, R. S., Zorzanelli, R., & Pieters, T. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00412 · Cited by 13
Pan, J., Lin, S. J., Qian, Q., Fu, S., & Liu, X. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1621678 · Cited by 13
Liu, M., Tian, X.-Y., Fang, T., Wu, N., Li, H., & Li, J. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03312-z · Cited by 11
Xu, S., Xu, D., Wen, L. G., Zhu, C., Yang, Y., Han, S., & Guan, P. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s270379 · Cited by 11
Psilocybin as a Novel Pharmacotherapy for Treatment-Refractory Anorexia Nervosa
Rodan, S.-C., Aouad, P., McGregor, I. S., & Maguire, S. (2021) · OBM Neurobiology · doi:10.21926/obm.neurobiol.2102102 · Cited by 13
Research into Psychedelic-Assisted Psychotherapy for Anorexia Nervosa Should be Funded
Otterman, L. S. (2022) · Journal of Bioethical Inquiry · doi:10.1007/s11673-022-10220-9 · Cited by 11
Miller, M., Rosa, W. E., Rinaldi, A. D., Addicott, K., Spence, D., & Beaussant, Y. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2022.0009 · Cited by 12
Desai, S. R., Jain, V., Xavier, S., & Du, W. (2022) · Children · doi:10.3390/children9121906 · Cited by 10
Exploring the Prevalence of PTSD in Hand Trauma: A Comprehensive Study
Ghiţan, A. F., Gheorman, V., Ciurea, M. E., Gheorman, V., Dinescu, V. C., Ciurea, A.-M., Militaru, F., Popa, R., Ţenea-Cojan, T.-Ş., & Udriștoiu, I. (2023) · Brain Sciences · doi:10.3390/brainsci13101438 · Cited by 9
Efthimiou, A. A., Cardinale, A. M., & Kepa, A. (2024) · Psychedelic Medicine · doi:10.1089/psymed.2023.0058 · Cited by 11
Butler, M., Bird, C., Maggio, C., Durden, A., Modlin, N. L., Campbell‐Coker, K., Edwards, M. J., Pick, S., Millman, L. S. M., Lowery, E., et al. (2024) · Wellcome Open Research · doi:10.12688/wellcomeopenres.22543.1 · Cited by 9
Psychoactive substances for the treatment of neuropsychiatric disorders
Zhen, Z., Sun, X., Yuan, S., & Zhang, J. (2024) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2024.104193 · Cited by 12
Smith, F. N., Neill, J. C., & Wainwright, V. (2022) · Drug Science Policy and Law · doi:10.1177/20503245221124117 · Cited by 13
Cohen, J., Sulimani, L., Procaccia, S., Lerenthal, Y., Milay, L., Taran, I., Shapira, A., & Meiri, D. (2025) · Scientific Reports · doi:10.1038/s41598-025-97710-z · Cited by 8
Nyazema, N. Z., Jonathan, T. C., & Egan, B. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1269247 · Cited by 8
Dong, J., Wei, R., Zong, F., Wang, Z., Ma, S., Zhao, W., Lin, Y., Zhang, A., Ge, L., Zhang, F., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1411652 · Cited by 8
The Psychiatric Domain of Post-Intensive Care Syndrome: A Review for the Intensivist
Rhodes, A., Wilson, C., Zelenkov, D., Adams, K., Poyant, J., Han, X., Faugno, A. J., & Montalvo, C. (2024) · Journal of Intensive Care Medicine · doi:10.1177/08850666241275582 · Cited by 9
Regulatory Challenges of Integrating Psychedelics into Mental Health Sector
Soylemez, K. K., de Boo, E. M., & Lusher, J. M. (2025) · Psychoactives · doi:10.3390/psychoactives4020011 · Cited by 13
Rajwani, K., Jacobs, E., Bruce, L., Hokanson, J., Almonte, M. T., Feroz, F., Waldman, E. D., Cheung, K., Levy, N. L., Savulescu, J., et al. (2025) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(25)00208-1 · Cited by 11
Palhas, M. L. C., Corne, R., & Mongeau, R. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111533 · Cited by 12
Metadata
- Authors
- Krediet, E., Bostoen, T., Breeksema, J., van Schagen, A., Passie, T., & Vermetten, E.
- Affiliations
- Leiden University Medical Center (NL)
- University Medical Center Groningen (NL)
- ARQ National Psychotrauma Center, Diemen, The Netherlands
- Goethe University Frankfurt (DE)
- Corresponding author
- Vermetten, Eric
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-03-14
- Volume
- 23
- Issue
- 6
- Pages
- 385-400
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC7311646
- OpenAlex
- W3011668650
- Cited by
- 260
- References
- 167
- Citations by year
- 2026: 21 · 2025: 62 · 2024: 54 · 2023: 43 · 2022: 44 · 2021: 24 · 2020: 11
- FWCI
- 2.40
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Leiden Repository (Leiden University) (submittedVersion, cc-by-nc)
- Data Archiving and Networked Services (DANS) (submittedVersion, cc-by-nc)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by-nc)
- Funders
- Universiteit Leiden
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Social Sciences › Psychology › Clinical Psychology › Posttraumatic Stress Disorder Research
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- post-traumatic stress disorder, psychedelics, MDMA, ketamine, psilocybin, LSD, cannabinoids, psychedelic-assisted psychotherapy, adjunctive therapy, psychiatric drug development
- MeSH terms
- Brain, Hallucinogens, Humans, Stress Disorders, Post-Traumatic, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.